Defence Therapeutics - President & CEO, Sébastien Plouffe
President & CEO, Sébastien Plouffe
Source: LinkedIn
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Defence Therapeutics Inc.’s (DTC) recent pre-clinical study showed hopeful results for its AccuTOX formulation on animals with pre-established lung cancer
  • When AccuTOX was administered as a combination therapy with an immune-checkpoint inhibitor, anti-PD1, it reduced the level of lung nodules by 50 per cent
  • This result was achieved with six administrated nasal passageway doses over two weeks
  • The company is preparing for a meeting to get approval for a phase one trial against solid tumours in 2023
  • Defence Therapeutics Inc. (DTC) is up 2.70 per cent and at $2.28 per share as of 10:08 a.m. EST

Defence Therapeutics’ (DTC) recently completed pre-clinical study showed hopeful results for its AccuTOX formulations on animals with pre-established lung cancer.

The study showed that when AccuTOX was administered as a combination therapy with an immune-checkpoint inhibitor, anti-PD1, it reduced the level of lung nodules by 50 per cent.

This result was achieved with six administrated nasal passageway doses over two weeks with the AccuTOX anti-PD1 combination plan. It was well tolerated at five to six times lower than the injectable dose.

Sebastien Plouffe, President and CEO of Defence, commented,

“The compound has not only shown a great potential in treating solid tumours, but we now have data demonstrating that it can be further adapted and delivered via the intranasal route to treat lungs with metastatic tumours… this will open up a completely new horizon for AccuTOX as an anti-cancer treatment.”

The AccuTOX program is one of Defence’s most advanced immune-oncology programs, which was originally designed to display enhanced anti-tumour properties compared to its original Accum molecule. The company is currently preparing for its U.S. Food and Drug Administration meeting regarding a phase one trial against solid tumours in 2023.

Defence Therapeutics Inc. (DTC) is up 2.70 per cent and is trading at $2.28 per share as of 10:08 a.m. EST.


More From The Market Herald

" @ the Bell: Tech leads TSX comeback

It was another rocky day for Canada’s main stock index that ultimately ended up in the green thanks to a lead powered by
Geomega Resources - President & CEO, Kiril Mugerman

" Geomega Resources (TSXV:GMA) granted $3M for recycling demo plant

Geomega Resources (GMA) has been awarded a $3 million grant from the government of Quebec’s Technoclimat Program.
First Hydrogen Corp. - CEO of Automotive, Steve Gill.

" First Hydrogen (TSXV:FHYD) unveils next gen FCEV images

First Hydrogen (FHYD) has received the initial Generation II images for its hydrogen fuel cell vehicle (FCEV), designed in collaboration with EDAG Group.
The Tugaske Project.

" Gensource Potash (TSXV:GSP) closes non-brokered private placement

Gensource Potash Corporation (GSP) has closed its previously announced non-brokered private placement of units and flow-through common shares.